RxDoctor Payments Data

Hiram Ruiz Santiago, MD

MOHS-Micrographic Surgery · Bayamon, PRNPI 1447249768

Payments from drug & device makers

$289,408in general payments, 2019–2025

Across 335 payments — averaging $863.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$244K
  • Johnson & Johnson$32K
  • E.r. Squibb & Sons, L.L.C.$6K
  • Sanofi$3K
  • Organon$2K
  • Novartis$405
  • plus $744 from 6 others

What the payments were for

  • Consulting fees$15,17514%
  • Speaking & faculty fees$82,38177%
  • Travel & lodging$1,7562%
  • Food & beverage$7,8807%
  • Education$3500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie204$244,362
Johnson & Johnson(2 entities)46$32,073
E.r. Squibb & Sons, L.L.C.18$6,097
Sanofi15$3,328
Organon1$2,400
Novartis22$405
Eli Lilly Export S.A. Puerto Rico Branch12$288
PBG Puerto Rico LLC8$165
Lilly USA, LLC1$119
Amgen4$82
Sanofi-aventis U.S. LLC2$50
LEO Pharma Inc.2$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few mohs-micrographic surgery providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$76,961
Medicare patients
155
Services billed
541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa74$1,551,618
Dupixent PenDupilumab130$499,608
TremfyaGuselkumab32$442,381
Taltz AutoinjectorIxekizumab43$296,131
StelaraUstekinumab11$154,552
Humira(Cf) PenAdalimumab21$143,391
Desonide212$25,883
Halobetasol Propionate177$11,996
Calcipotriene43$9,521
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc176$8,865
Fluocinolone AcetonideFluocinolone/Shower Cap89$6,302
Mometasone Furoate182$5,373
Metronidazole50$5,002
Ketoconazole181$4,304
Hydrocortisone Butyrate22$2,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya, Stelara$32,073$596,93443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few mohs-micrographic surgery providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other mohs-micrographic surgery in Bayamon

Where these figures come from

Is this you, or does something look wrong? →